A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Administered By

Awarded By

Contributors

Start/End

  • August 15, 2016 - April 4, 2018